{
  "source": "PA-Med-Nec-Firazyr-icatibant-Sajazir.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2209-7\nProgram Prior Authorization/Medical Necessity\nMedication Firazyr® (icatibant)*, icatibant, Sajazir™ (icatibant)*\nP&T Approval Date 6/2020, 4/2021, 4/2022, 4/2023, 2/2024, 4/2024, 4/2025\nEffective Date 7/1/2025\n1. Background:\nFirazyr (icatibant)* is a bradykinin B2 receptor antagonist indicated for treatment of acute\nattacks of hereditary angioedema (HAE) in adults 18 years of age and older. Sajazir\n(icatibant)* injection is a bradykinin B2 receptor antagonist indicated for treatment of acute\nattacks of HAE in adults 18 years of age and older.\n2. Coverage Criteria a:\nA. Initial Authorization\n1. Firazyr*, icatibant, or Sajazir* will be approved based on all of the following criteria:\na. Diagnosis of hereditary angioedema (HAE) as confirmed by one of the following:\n(1) C1 inhibitor (C1-INH) deficiency or dysfunction (Type I or II HAE) as documented\nby one of the following (per laboratory standard):\n(a) C1-INH antigenic level below the lower limit of normal\n(b) C1-INH functional level below the lower limit of normal\n-OR-\n(2) HAE with normal C1 inhibitor levels and one of the following:\n(a) Confirmed presence of variant(s) in the gene(s) for factor XII, angiopoietin-1,\nplasminogen-1, kininogen-1, myoferlin, or heparan sulfate-glucosamine 3-O-\nsulfotransferase 6\n(b) Recurring angioedema attacks that are refractory to high-dose antihistamines\nwith confirmed family history of angioedema\n(c) Recurring angioedema attacks that are refractory to high-dose antihistamines\nwith unknown background de-novo mutation(s) (i.e., no family history) (HAE-\nunknown)\n-AND-\nb. Both of the following:\n(1) Prescribed for the acute treatment of HAE attacks\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\n(2) Not used in combination with other products indicated for the acute treatment of\nHAE attacks (e.g., Berinert, Kalbitor, or Ruconest)\n-AND-\nc. Prescribed by one of the following:\n(1) Immunologist\n(2) Allergist\nAuth",
    "ombination with other products indicated for the acute treatment of\nHAE attacks (e.g., Berinert, Kalbitor, or Ruconest)\n-AND-\nc. Prescribed by one of the following:\n(1) Immunologist\n(2) Allergist\nAuthorization of therapy will be issued for 12 months.\nB. Reauthorization\n1. Firazyr*, icatibant, or Sajazir* will be approved based on all of the following criteria:\na. Documentation of positive clinical response to icatibant therapy\n-AND-\nb. Both of the following:\n(1) Prescribed for the acute treatment of HAE attacks\n-AND-\n(2) Not used in combination with other products indicated for the acute treatment of\nHAE attacks (e.g., Berinert, Kalbitor, or Ruconest)\n-AND-\nc. Prescribed by one of the following:\n(1) Immunologist\n(2) Allergist\nAuthorization of therapy will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n* Firazyr (brand) and Sajazir are typically excluded from coverage. Coverage reviews may be in\nplace if required by law or the benefit plan.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\n© 2025 UnitedHealthcare Services, Inc.\n2\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Firazyr [package insert]. Lexington, MA: Shire Orphan Therapies, LLC; January 2024.\n2. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the\nmanagement of hereditary angioedema-The 2017 revision and update. Allergy. 2018 Jan 10.\n3. Wu, E. Hereditary angioedema with normal C1 inhibitor. In: UpToDate, Saini, S (Ed),\nUpToDate, Waltham, MA, 2023.\n4. Busse, P., Christiansen, S., Riedl., M., et. al. “US HAEA Medical Ad",
    "2018 Jan 10.\n3. Wu, E. Hereditary angioedema with normal C1 inhibitor. In: UpToDate, Saini, S (Ed),\nUpToDate, Waltham, MA, 2023.\n4. Busse, P., Christiansen, S., Riedl., M., et. al. “US HAEA Medical Advisory Board 2020\nGuidelines for the Management of Hereditary Angioedema.” The Journal of Allergy and Clinical\nImmunology. 2020 September 05.\n5. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the\nmanagement of hereditary angioedema-The 2021 revision and update. Allergy. 2022;77(7):1961-\n1990. doi:10.1111/all.15214\n6. Sajazir [package insert]. Cambridge, CB3 0FA, United Kingdom: Cycle Pharmaceuticals Ltd;\nFebruary 2024.\nProgram Prior Authorization/Medical Necessity - Firazyr (icatibant), Sajazir\n(icatibant)\nChange Control\n6/2020 New program.\n4/2021 Added diagnosis criteria. Updated references.\n4/2022 Updated references.\n4/2023 Annual review. Added Sajazir, updated background, and updated\nreferences.\n2/2024 Added coverage exclusion statement for brand Firazyr and Sajazir. Added\nKalbitor to list of other products indicated for the acute treatment of HAE\nattacks.\n4/2024 Update to examples of genetic variant(s) and diagnostic criteria with\nnormal C1 inhibitor levels. Updated language for reauthorization criteria.\nUpdated references.\n4/2025 Annual review. No changes to coverage criteria. Updated reference.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}